more

SESEN BIO, INC. (SESN)

(Delayed Data from NSDQ)

$1.30 USD

+0.07 (5.69%)

Updated May 3, 2019 04:00 PM ET

After-Market: $1.30 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.15%
2	Buy	17.88%
3	Hold	9.47%
4	Sell	5.14%
5	Strong Sell	2.57%
S&P	500	11.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

Industry: NA

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Pfizer (PFE) Reports More Positive Data From Etrasimod Study

by Zacks Equity Research Published on May 25,2022

Pfizer (PFE) states that data from the ELEVATE 12 and ELEVATE 52 studies will form the basis of the regulatory submissions on etrasimod expected later this year

pharmaceuticals

Merck (MRK) Keytruda Gets EU Nod for Expanded Breast Cancer Use

by Zacks Equity Research Published on May 25,2022

The European Commission approves Merck's (MRK) Keytruda for high-risk early-stage TNBC, which expands its eligible patient population.

pharmaceuticals

Sanofi, Regeneron's Dupixent Gets FDA Nod for 4th Indication (Revised)

by Zacks Equity Research Published on May 25,2022

The FDA approves Sanofi's (SNY) Dupixent for treating adults and children aged 12 and older with eosinophilic esophagitis, a chronic, progressive inflammatory disease.

pharmaceuticals

Biohaven's (BHVN) Zavegepant NDA for Migraine Accepted by FDA

by Zacks Equity Research Published on May 24,2022

The FDA accepts Biohaven's (BHVN) NDA seeking approval for its pipeline candidate, zavegepant, as an intra-nasal treatment for migraine. A decision is expected early next year.

biotechs

Sanofi, Regeneron's Dupixent Gets FDA Nod for 4th Indication

by Zacks Equity Research Published on May 23,2022

The FDA approves Sanofi's (SNY) Dupixent for treating adults and children aged 12 and older with eosinophilic esophagitis, a chronic, progressive inflammatory disease.

pharmaceuticals

Merck's (MRK) Keytruda Gets CHMP Nod for Expanded Melanoma Use

by Zacks Equity Research Published on May 23,2022

Merck's (MRK) anti-PD-1 therapy Keytruda nears potential approval as an adjuvant treatment for adolescent pediatric patients with stage IIB, IIC or III melanoma following complete resection.

pharmaceuticals

Merck (MRK) Outperforms Industry This Year So Far: Here's Why

by Zacks Equity Research Published on May 19,2022

Strong sales of key products like Keytruda and Gardasil, a significant contribution from Lagevrio and positive pipeline/regulatory developments have been keeping Merck's (MRK) stock afloat in 2022.

pharmaceuticals

AbbVie (ABBV) Buys Option Rights to NextGen Inflammation Drug

by Zacks Equity Research Published on May 17,2022

AbbVie (ABBV) receives the option to license worldwide rights for certain IL-2 muteins, including the next-generation inflammatory candidate, CUG252 from Cugene

pharmaceuticals

Chimerix (CMRX) Plunges on Unfavorable Pipeline Updates

by Zacks Equity Research Published on May 17,2022

The development of Chimerix's (CMRX) lead candidate, ONC201, gets delayed as the FDA states that data from the retrospective study is unlikely to support an approval. The company ends the DSTAT program.

pharmaceuticals

CRISPR (CRSP) Focuses on Pipeline Amid Lack of Marketed Drugs

by Zacks Equity Research Published on May 16,2022

While CRISPR Therapeutics' (CRSP) lead candidate is still a couple of years away from commercialization, it is highly dependent on collaboration revenues to fund its ongoing pipeline.

Will Repligen's (RGEN) COVID Woes Be Offset by Product Demand?

by Zacks Equity Research Published on May 16,2022

The declining pace of COVID-19 vaccination programs is likely to hurt Repligen's (RGEN) revenue growth rate in 2022. However, the strong core business is likely to offer a respite.

biotechs

Lilly's (LLY) Diabetes Treatment Tirzepatide Gets FDA Nod

by Zacks Equity Research Published on May 16,2022

Lilly's (LLY) Mounjaro (tirzepatide) is a novel diabetes treatment, which has shown impressive blood sugar reductions and weight loss in a broad range of type II diabetes patients in the SURPASS studies.

pharmaceuticals

Are Options Traders Betting on a Big Move in Sesen Bio (SESN) Stock?

by Zacks Equity Research Published on December 08,2021

Investors need to pay close attention to Sesen Bio (SESN) stock based on the movements in the options market lately.

SESNPositive Net Change

medical

SESEN BIO, INC. (SESN) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research Published on November 08,2021

SESEN BIO, INC. (SESN) delivered earnings and revenue surprises of 71.43% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

SESNPositive Net Change

SESEN BIO, INC. (SESN) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

by Zacks Equity Research Published on November 01,2021

SESEN BIO, INC. (SESN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

SESNPositive Net Change

Implied Volatility Surging for Sesen Bio (SESN) Stock Options

by Zacks Equity Research Published on September 27,2021

Investors need to pay close attention to Sesen Bio (SESN) stock based on the movements in the options market lately.

SESNPositive Net Change

medical

Do Options Traders Know Something About Sesen Bio (SESN) Stock We Don't?

by Zacks Equity Research Published on August 20,2021

Investors need to pay close attention to Sesen Bio (SESN) stock based on the movements in the options market lately.

SESNPositive Net Change

Sesen's (SESN) Bladder Cancer Drug Vicineum Gets CRL From FDA

by Zacks Equity Research Published on August 16,2021

Sesen's (SESN) biologics license application filed for Vicineum to treat BCG-unresponsive non-muscle invasive bladder cancer fails to secure approval. The stock declines resultantly.

SESEN BIO, INC. (SESN) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research Published on August 09,2021

SESEN BIO, INC. (SESN) delivered earnings and revenue surprises of -16.67% and -6.92%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?